This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): MK-0608
Description: MK-0608 is a HCV Polymerase Inhibitor.
Deal Structure: In June 1998, Isis entered into a multi-year research collaboration and license agreement with Merck to discover small molecule drug candidates to treat patients infected with HCV. The research collaboration ended in May 2003 in accordance with its terms. In December 2006, Merck advanced MK-0608, a drug discovered in this collaboration, into Phase I clinical trials for which Isis earned a $1 million milestone payment. In addition, Merck will pay Isis aggregate milestone payments of up to $16 million upon the achievement of key clinical and regulatory milestones, and royalties on future product sales.
Partners: Ionis Pharmaceuticals, Inc.
Pink Sheet STAT-C Agents In Development For Hepatitis C
Additional information available to subscribers only: